Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jazz Pharma Plc
(NQ:
JAZZ
)
108.39
-0.25 (-0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharma Plc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
Prediction: These Could Be the Best-Performing Cannabis Stocks Through 2030
August 26, 2023
These two businesses may be sound, but generating returns in this industry has been tough, with no light at the end of the tunnel.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Epidiolex Counterpart Debuts In Brazil's Cannabis Market As Its Maker Eyes TSX IPO
August 23, 2023
Verdemed, a pharmaceutical company known for producing cannabis-derived products, has received five fresh approvals from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Jazz Pharmaceuticals' Neuroscience Pipeline Readouts In Focus: Analyst Lowers Price Target
August 14, 2023
Cantor Fitzgerald analyst Charles C.
Via
Benzinga
Expert Ratings for Jazz Pharmaceuticals
August 10, 2023
Via
Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
July 11, 2023
Via
Benzinga
Is Axsome Therapeutics Stock a Screaming Buy?
June 15, 2023
The biotech could be staring down an enormous commercial opportunity.
Via
The Motley Fool
Expert Ratings for Jazz Pharmaceuticals
June 05, 2023
Via
Benzinga
Cannabis Stock Gainers And Losers From August 11, 2023
August 11, 2023
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Jazz Pharmaceuticals Reports Q2 2023 Net Income Of $104.4M, What About Total Revenues?
August 09, 2023
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year.
Via
Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
May 15, 2023
Via
Benzinga
Recap: Jazz Pharmaceuticals Q1 Earnings
May 10, 2023
Via
Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon
August 08, 2023
These top biotech stocks are must-buys with huge potential, leading the industry with high-rewards for investors.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
August 08, 2023
Via
Benzinga
GOP Rep. Blasts FDA Over CBD Inaction During Historic Hearing: The Agency Wants More Money To Do Its Job
July 28, 2023
For the first time, Congress officially addressed the impact of the U.S. Food and Drug Administration’s (FDA) inaction regarding the regulations of CBD products.
Via
Benzinga
FDA, Get It Done! Says Senator In Bipartisan Push To Regulate CBD Products Prior To Committee Hearing
July 21, 2023
A bipartisan group of U.S. lawmakers reintroduceda measure on Wednesdaythat aims to secure theFood and Drug ...
Via
Benzinga
Divided GOP Helps This State Dodge Bullet From The Pot Lobby, Says Anti-Marijuana Group
July 10, 2023
Is the battle for medical marijuana legalization in North Carolina over for this year? Some groups say yes, some say know, here is what happened.
Via
Benzinga
4 Unequaled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
July 08, 2023
Bargains are hiding in plain sight with the Nasdaq Composite still well below its November 2021 record-closing high.
Via
The Motley Fool
Jazz Pharmaceuticals Sues FDA Over Approval Of Rival Product, Calls It 'Unlawful'
June 23, 2023
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel Pharmaceuticals Plc's (NASDAQ: AVDL) Lumryz (sodium oxybate extended-release) for cataplexy or excessive day
Via
Benzinga
10 Cannabis Stocks That Could Go Sky High In 2023
June 18, 2023
With cannabis legalization gaining momentum, investing in cannabis presents a lucrative opportunity. Investors may want to explore cannabis stocks to enhance their portfolios. Here are the top 10...
Via
Talk Markets
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
June 13, 2023
On Tuesday, 32 companies reached new 52-week lows.
Via
Benzinga
3 Cheap Growth Stocks That Are Too Good to Pass Up
June 05, 2023
These top bargain growth stocks are all priced under $10 a share and offer real upside potential for investors.
Via
InvestorPlace
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
May 31, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
FDA Presents Potential Framework For CBD, From Edibles To Delta-8, Reaffirms Congress Is In Charge
May 30, 2023
The U.S. Food and Drug Administration has not given up on regulating CBD and hemp-derived products in a way that would be safe for consumers and producers.
Via
Benzinga
Ford To Rally Around 33%? Here Are 10 Other Analyst Forecasts For Tuesday
May 30, 2023
Keybanc boosted the price target for Broadcom Inc. (NASDAQ: AVGO) from $720 to $820. Keybanc analyst John Vinh maintained the stock with an Overweight rating. Broadcom shares rose 11.5% to close at...
Via
Benzinga
Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
May 25, 2023
Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical...
Via
Benzinga
World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients
May 25, 2023
Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project...
Via
Benzinga
Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?
May 11, 2023
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2023, revealing revenue of $892.8 million, an increase of 10% compared to $813.7 million in Q1 2022.
Via
Benzinga
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
May 09, 2023
The biotech's share price more than doubled during last year's bear market.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.